|
|
|
|
Micrograph of multilamellar liposomes (MLV) |
Uptake of small, calcein encapsulating liposomes (green) into kidney cells after 24 h of incubation. Red: cell membrane |
EPO offers the encapsulation of
substances provided by the costumer into microspheres (liposomes and
nanoparticles) to improve their pharmacological properties.
Why microencapsulation of active compounds?
Protection of compounds from degradation
Change of body distribution and kinetics
Reduction of side effects
Enables an active targeting without a change in the structure of the active compound
Enables a controlled release of the active compound
Enables an synchronic transport and targeting of two active compounds which are completely different in their properties
For each pharmacologically
active compound a specific formulation has to be developed
Preparation of liposomes (nanoparticles) with entrapped drug
Characterisation of vesicles (size, lipid and drug concentration, stability in buffer or serum)
Modification of vesicle surface (pegylation, antibody conjugation)
Testing of pharmacological properties of the encapsulated compound in vitro and in vivo
|
|
|
|
Micrograph of multilamellar liposomes (MLV) |
Uptake of small, calcein encapsulating liposomes (green) into kidney cells after 24 h of incubation. Red: cell membrane |
Copyright © 2007 of EPO GmbH - All rights reserved. 12. März 2008.
Top